RPP8 Antibody

Role in Viral Immunity and Vaccine Development

Studies on cross-reactive antibodies highlight the utility of ribosomal proteins like RPL8 as indirect biomarkers. For example:

• Antibodies targeting influenza virus hemagglutinin (HA) showed enhanced CD8+ T cell responses when paired with ribosomal protein antigens, suggesting adjuvant potential ( ).

• RPL8’s conserved structure across species (human, mouse, rat) makes it a reliable control in comparative studies ( ).

Diagnostic and Therapeutic Implications

• Autoimmune Diseases: Anti-ribosomal P protein antibodies (including RPL8 homologs) correlate with systemic lupus erythematosus (SLE) disease activity, particularly lupus nephritis (specificity: 99.2%; sensitivity: 31.6%) ( ).

• Cancer Research: Reverse phase protein arrays (RPPA) utilizing RPL8 antibodies identified dysregulated ribosomal pathways in non-small cell lung cancer (NSCLC) and renal carcinomas ( ).

Validation and Reliability

Antibody validation remains critical for reproducibility:

• RPPA vs. Mass Spectrometry: Proteins measured with validated antibodies (e.g., RPL8) show higher mRNA-protein correlation (median r = 0.45) compared to less reliable reagents (r = 0.28) ( ).

• Epitope Stability: Cyclic peptide antigens (e.g., CR1/CR2 domains in LRP8 antibodies) improve antibody specificity by mimicking native protein conformations ( ).

Limitations and Future Directions

• Cross-Reactivity: Polyclonal RPL8 antibodies may bind off-target epitopes in complex lysates, necessitating KO validation ( ).

• Automation: High-throughput screening systems (e.g., RAPID) aim to standardize antibody validation, reducing batch variability ( ).